{
    "eid": "2-s2.0-85168954109",
    "title": "In vitro and in vivo studies of plant-produced Atezolizumab as a potential immunotherapeutic antibody",
    "cover-date": "2023-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Multidisciplinary",
            "@code": "1000",
            "@abbrev": "MULT"
        }
    ],
    "keywords": [],
    "authors": [
        "Kaewta Rattanapisit",
        "Christine Joy I. Bulaon",
        "Richard Strasser",
        "Hongyan Sun",
        "Waranyoo Phoolcharoen"
    ],
    "citedby-count": 0,
    "ref-count": 57,
    "ref-list": [
        "Global cancer incidence and mortality rates and trends\u2014An update",
        "A guide to cancer immunotherapy: from T cell basic science to clinical practice",
        "Anti-PD-1 and Anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations",
        "Immune checkpoint signaling and cancer immunotherapy",
        "Immune checkpoint blockade: A common denominator approach to cancer therapy",
        "Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)",
        "PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer",
        "Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management",
        "A phase 1/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia",
        "Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors",
        "Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges",
        "Treating with checkpoint inhibitors-figure $1 million per patient",
        "The production of hemagglutinin-based virus-like particles in plants: A rapid, efficient and safe response to pandemic influenza",
        "Predictive models for transient protein expression in tobacco (Nicotiana tabacum L.) can optimize process time, yield, and downstream costs",
        "Techno-economic analysis of a transient plant-based platform for monoclonal antibody production",
        "A simplified techno-economic model for the molecular pharming of antibodies",
        "The potential of plants as a system for the development and production of human biologics",
        "Plant-based production of biopharmaceuticals",
        "High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system",
        "Production, characterization, and antigen specificity of recombinant 62\u201371-3, a candidate monoclonal antibody for rabies prophylaxis in humans",
        "Structural and in vitro functional analyses of novel plant-produced anti-human PD1 antibody",
        "Expression of plant-produced anti-PD-L1 antibody with anoikis sensitizing activity in human lung cancer cells via., suppression on epithelial-mesenchymal transition",
        "Functional characterization of pembrolizumab produced in Nicotiana benthamiana using a rapid transient expression system",
        "Biologics vs. small molecules: Drug costs and patient access",
        "The economic potential of plant-made pharmaceuticals in the manufacture of biologic pharmaceuticals",
        "Plants as factories for human pharmaceuticals: Applications and challenges",
        "Plant molecular farming: Much more than medicines",
        "Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plants",
        "Modifying the replication of geminiviral vectors reduces cell death and enhances expression of biopharmaceutical proteins in Nicotiana benthamiana leaves",
        "The C-terminal KDEL sequence increases the expression level of a single-chain antibody designed to be targeted to both the cytosol and the secretory pathway in transgenic tobacco",
        "A KDEL-tagged monoclonal antibody is efficiently retained in the endoplasmic reticulum in leaves, but is both partially secreted and sorted to protein storage vacuoles in seeds",
        "Efficient in vitro and in vivo activity of glyco-engineered plant-produced rabies monoclonal antibodies E559 and 62\u201371\u20133",
        "Development of plant-produced recombinant ACE2-Fc fusion protein as a potential therapeutic agent against SARS-CoV-2",
        "Development of a plant-produced recombinant monoclonal antibody against \u0394-9-tetrahydrocannabinol (\u03949-THC) for immunoassay application",
        "Carboxy-terminal SEKDEL sequences retard but do not retain two secretory proteins in the endoplasmic reticulum",
        "Efficacy of a food plant-based oral cholera toxin B subunit vaccine",
        "Synthesis of a cholera toxin B subunit-rotavirus NSP4 fusion protein in potato",
        "Monoclonal antibodies B38 and H4 produced in Nicotiana benthamiana neutralize SARS-CoV-2 in vitro",
        "Vertebrate protein glycosylation: Diversity, synthesis and function",
        "The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: Properties of a series of truncated glycoforms",
        "Plant protein glycosylation",
        "The C-terminal HDEL sequence is sufficient for retention of secretory proteins in the endoplasmic reticulum (ER) but promotes vacuolar targeting of proteins that escape the ER",
        "High resolution mapping of the binding site on human IgG1 for Fc\u03b3RI, Fc\u03b3RII, Fc\u03b3RIII, and FcRn and design of IgG1 variants with improved binding to the Fc\u03b3R *",
        "Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region",
        "Aggregation of protein therapeutics enhances their immunogenicity: Causes and mitigation strategies",
        "Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo",
        "Glyco-engineered anti-human programmed death-ligand 1 antibody mediates stronger CD8 T cell activation than its normal glycosylated and non-glycosylated counterparts",
        "Reduced FcRn-mediated transcytosis of IgG2 due to a missing Glycine in its lower hinge",
        "New PD-L1 inhibitors in non-small cell lung cancer\u2014Impact of atezolizumab",
        "Atezolizumab in invasive and metastatic urothelial carcinoma",
        "Atezolizumab and bevacizumab for hepatocellular carcinoma: Mechanism, pharmacokinetics and future treatment strategies",
        "Rhein augments antiproliferative effects of atezolizumab based on breast cancer (4T1) regression",
        "Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential",
        "A global pharmaceutical company initiative: An evidence-based approach to define the upper limit of body weight loss in short term toxicity studies",
        "Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Vienna",
            "@id": "60024895",
            "affilname": "Universitat fur Bodenkultur Wien",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60024895",
            "affiliation-country": "Austria"
        },
        {
            "affiliation-city": "Nanjing",
            "@id": "126148186",
            "affilname": "Ltd.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126148186",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "120504756",
            "affilname": "Ltd.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/120504756",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "BOKU Core Facility Mass Spectroscopy",
        "National Research Council of Thailand and Baiya Phytopharm Co., Ltd."
    ]
}